{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:41:23Z","timestamp":1780605683904,"version":"3.54.1"},"reference-count":6,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perfusion"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tremelimumab in combination with Durvalumab has recently been approved for the treatment of unresectable hepatocellular carcinoma (HCC). While immune checkpoint inhibitors (ICIs) have transformed cancer therapy, they are associated with rare but potentially fatal immune-related adverse events, including myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a case of fulminant myocarditis in a 66-year-old female with advanced HCC, 38 days after initiating the Tremelimumab\/Durvalumab STRIDE protocol. She presented with cardiogenic shock requiring V-A ECMO support. High-dose corticosteroid therapy resulted in full recovery of cardiac function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>ICI-associated myocarditis has a reported prevalence of 1.14%, with a high rate of major adverse cardiac events. We reported a case of Tremelimumab\/Durvalumab-associated myocarditis requiring mechanical circulatory support. Prompt recognition and immunosuppression were critical for recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinicians should maintain a high index of suspicion for myocarditis in patients on ICI therapy, as early intervention can be lifesaving.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02676591251363379","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:55:12Z","timestamp":1753761312000},"page":"490-493","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Veno-arterial extracorporeal membrane oxygenation support for cardiogenic shock secondary to immune checkpoint inhibitors"],"prefix":"10.1177","volume":"41","author":[{"given":"Quynh","family":"Nguyen","sequence":"first","affiliation":[{"name":"University of British Columbia"},{"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3831-8789","authenticated-orcid":false,"given":"Hossein","family":"Shayan","sequence":"additional","affiliation":[{"name":"University of British Columbia"},{"name":"Royal Columbian Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.05.014"},{"key":"e_1_3_4_4_2","first-page":"e43628","article-title":"An uncommon case of myocarditis secondary to durvalumab plus tremelimumab","volume":"15","author":"Diaz-Rodriguez PE","year":"2023","unstructured":"Diaz-Rodriguez PE, Muns-Aponte CM, Velazquez-Acevedo SI, et al. An uncommon case of myocarditis secondary to durvalumab plus tremelimumab. Cureus 2023; 15: e43628.","journal-title":"Cureus"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"e0281296","DOI":"10.1371\/journal.pone.0281296","article-title":"10-year survival outcome after clinically suspected acute myocarditis in adults: a nationwide study in the pre-COVID-19 era","volume":"18","author":"Kim M-J","year":"2023","unstructured":"Kim M-J, Jung HO, Kim H, et al. 10-year survival outcome after clinically suspected acute myocarditis in adults: a nationwide study in the pre-COVID-19 era. PLoS One 2023; 18: e0281296.","journal-title":"PLoS One"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"}],"container-title":["Perfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02676591251363379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02676591251363379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02676591251363379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:23:30Z","timestamp":1778127810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02676591251363379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/02676591251363379"],"URL":"https:\/\/doi.org\/10.1177\/02676591251363379","relation":{},"ISSN":["0267-6591","1477-111X"],"issn-type":[{"value":"0267-6591","type":"print"},{"value":"1477-111X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}